Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study
Compose a Response to This Article
Other responses
No responses have been published for this article.